Cite
HARVARD Citation
Visentin, A. et al. (2022). Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study. American journal of hematology. 97 (3), pp. E95-E99. [Online].